25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SAGE (Sage Therapeutic) Stock Analysis
Buy, Hold or Sell?

Let's analyze Sage Therapeutic together

I guess you are interested in Sage Therapeutic. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Sage Therapeuticโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Sage Therapeuticโ€™s Price Targets

I'm going to help you getting a better view of Sage Therapeutic. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Sage Therapeutic

I send you an email if I find something interesting about Sage Therapeutic.

1. Quick Overview

1.1. Quick analysis of Sage Therapeutic (30 sec.)










1.2. What can you expect buying and holding a share of Sage Therapeutic? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$6.54
Expected worth in 1 year
$1.82
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-4.73
Return On Investment
-51.0%

For what price can you sell your share?

Current Price per Share
$9.27
Expected price per share
$8.76 - $11.44
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Sage Therapeutic (5 min.)




Live pricePrice per Share (EOD)
$9.27
Intrinsic Value Per Share
$-64.73 - $-7.62
Total Value Per Share
$-58.19 - $-1.08

2.2. Growth of Sage Therapeutic (5 min.)




Is Sage Therapeutic growing?

Current yearPrevious yearGrowGrow %
How rich?$409.8m$826.5m-$312.8m-60.9%

How much money is Sage Therapeutic making?

Current yearPrevious yearGrowGrow %
Making money-$88.5m-$125.7m$37.1m42.0%
Net Profit Margin-791.6%-3,829.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Sage Therapeutic (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#151 / 872

Most Revenue
#276 / 872

Most Profit
#833 / 872

Most Efficient
#681 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Sage Therapeutic?

Welcome investor! Sage Therapeutic's management wants to use your money to grow the business. In return you get a share of Sage Therapeutic.

First you should know what it really means to hold a share of Sage Therapeutic. And how you can make/lose money.

Speculation

The Price per Share of Sage Therapeutic is $9.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sage Therapeutic.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sage Therapeutic, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.54. Based on the TTM, the Book Value Change Per Share is $-1.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sage Therapeutic.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.99-10.7%-1.41-15.3%-2.01-21.7%-1.88-20.3%-1.01-10.9%-1.18-12.7%
Usd Book Value Change Per Share-0.88-9.5%-1.18-12.7%-1.71-18.4%-1.61-17.4%-0.35-3.8%0.121.3%
Usd Dividend Per Share0.000.0%0.000.0%0.030.3%0.010.1%0.010.1%0.000.0%
Usd Total Gains Per Share-0.88-9.5%-1.18-12.7%-1.68-18.1%-1.60-17.2%-0.34-3.7%0.131.3%
Usd Price Per Share7.95-7.87-27.00-24.25-36.59-64.51-
Price to Earnings Ratio-2.00--1.44--4.82--3.50--4.49--15.16-
Price-to-Total Gains Ratio-9.01--6.90--29.91--18.83--24.09--20.65-
Price to Book Ratio1.21-0.96-1.98-1.59-1.98-6.65-
Price-to-Total Gains Ratio-9.01--6.90--29.91--18.83--24.09--20.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.27
Number of shares107
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-1.18-0.35
Usd Total Gains Per Share-1.18-0.34
Gains per Quarter (107 shares)-126.42-36.68
Gains per Year (107 shares)-505.68-146.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-506-5163-150-157
20-1011-10227-300-304
30-1517-152810-450-451
40-2023-203414-601-598
50-2528-254017-751-745
60-3034-304621-901-892
70-3540-355224-1051-1039
80-4045-405827-1201-1186
90-4551-456431-1351-1333
100-5057-507034-1501-1480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%1.048.01.02.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%8.032.00.020.0%11.036.03.022.0%
Dividend per Share0.00.04.00.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%5.00.045.010.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%8.032.00.020.0%11.036.03.022.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Sage Therapeutic compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.882-1.182+34%-1.706+93%-1.608+82%-0.351-60%0.121-828%
Book Value Per Share--6.5458.203-20%13.200-50%14.147-54%18.537-65%14.281-54%
Current Ratio--9.1309.128+0%10.026-9%11.336-19%15.958-43%15.634-42%
Debt To Asset Ratio--0.1270.122+4%0.101+26%0.098+30%0.083+53%0.083+53%
Debt To Equity Ratio--0.1460.140+4%0.113+29%0.110+33%0.092+59%0.093+57%
Dividend Per Share----0%0.028-100%0.013-100%0.008-100%0.004-100%
Enterprise Value--861880285.000958513639.500-10%2434642405.750-65%2331548830.750-63%3377122762.750-74%4882802087.025-82%
Eps---0.993-1.415+42%-2.009+102%-1.883+90%-1.008+1%-1.177+18%
Ev To Ebitda Ratio---3.194-2.689-16%-6.128+92%-5.025+57%-6.547+105%-16.345+412%
Ev To Sales Ratio--15.32221.647-29%160.097-90%202.197-92%386.455-96%904.577-98%
Free Cash Flow Per Share---1.305-1.242-5%-1.697+30%-1.654+27%-0.741-43%-0.902-31%
Free Cash Flow To Equity Per Share---1.303-1.205-8%-1.677+29%-1.630+25%-0.377-71%0.107-1313%
Gross Profit Margin--1.0001.0000%1.0020%1.0010%1.0000%1.025-2%
Intrinsic Value_10Y_max---7.623----------
Intrinsic Value_10Y_min---64.733----------
Intrinsic Value_1Y_max---3.202----------
Intrinsic Value_1Y_min---6.637----------
Intrinsic Value_3Y_max---7.763----------
Intrinsic Value_3Y_min---19.930----------
Intrinsic Value_5Y_max---10.084----------
Intrinsic Value_5Y_min---33.107----------
Market Cap580508721.000+14%497847285.000492524389.500+1%1690958655.750-71%1518747330.750-67%2291506512.750-78%4039874162.025-88%
Net Profit Margin---4.424-7.916+79%-38.297+766%-35.735+708%-49.273+1014%-57.580+1202%
Operating Margin---4.805-8.120+69%-37.491+680%-37.522+681%-49.427+929%-58.957+1127%
Operating Ratio--5.7979.539-39%38.472-85%38.655-85%50.506-89%72.489-92%
Pb Ratio1.416+14%1.2150.962+26%1.982-39%1.594-24%1.980-39%6.648-82%
Pe Ratio-2.333-17%-2.001-1.437-28%-4.817+141%-3.501+75%-4.495+125%-15.163+658%
Price Per Share9.270+14%7.9507.865+1%27.003-71%24.253-67%36.593-78%64.512-88%
Price To Free Cash Flow Ratio-1.776-17%-1.523-1.572+3%-4.639+205%-3.641+139%-4.971+226%-128.433+8334%
Price To Total Gains Ratio-10.509-17%-9.012-6.903-23%-29.908+232%-18.826+109%-24.090+167%-20.650+129%
Quick Ratio--16.33716.092+2%17.713-8%20.149-19%26.737-39%24.432-33%
Return On Assets---0.132-0.151+14%-0.135+2%-0.127-4%-0.084-37%-0.110-17%
Return On Equity---0.152-0.173+14%-0.1510%-0.142-7%-0.095-38%-0.122-19%
Total Gains Per Share---0.882-1.182+34%-1.678+90%-1.595+81%-0.343-61%0.125-805%
Usd Book Value--409848000.000513708500.000-20%826591500.000-50%885940500.000-54%1160854550.000-65%894335925.000-54%
Usd Book Value Change Per Share---0.882-1.182+34%-1.706+93%-1.608+82%-0.351-60%0.121-828%
Usd Book Value Per Share--6.5458.203-20%13.200-50%14.147-54%18.537-65%14.281-54%
Usd Dividend Per Share----0%0.028-100%0.013-100%0.008-100%0.004-100%
Usd Enterprise Value--861880285.000958513639.500-10%2434642405.750-65%2331548830.750-63%3377122762.750-74%4882802087.025-82%
Usd Eps---0.993-1.415+42%-2.009+102%-1.883+90%-1.008+1%-1.177+18%
Usd Free Cash Flow---81728000.000-77772500.000-5%-106265750.000+30%-103588666.667+27%-46434300.000-43%-56514550.000-31%
Usd Free Cash Flow Per Share---1.305-1.242-5%-1.697+30%-1.654+27%-0.741-43%-0.902-31%
Usd Free Cash Flow To Equity Per Share---1.303-1.205-8%-1.677+29%-1.630+25%-0.377-71%0.107-1313%
Usd Market Cap580508721.000+14%497847285.000492524389.500+1%1690958655.750-71%1518747330.750-67%2291506512.750-78%4039874162.025-88%
Usd Price Per Share9.270+14%7.9507.865+1%27.003-71%24.253-67%36.593-78%64.512-88%
Usd Profit---62214000.000-88599250.000+42%-125786000.000+102%-115007000.000+85%-61245300.000-2%-72787425.000+17%
Usd Revenue--14063000.00011851000.000+19%22766000.000-38%12322250.000+14%63383550.000-78%36427450.000-61%
Usd Total Gains Per Share---0.882-1.182+34%-1.678+90%-1.595+81%-0.343-61%0.125-805%
 EOD+5 -3MRQTTM+19 -18YOY+20 -203Y+20 -205Y+9 -3110Y+10 -30

3.3 Fundamental Score

Let's check the fundamental score of Sage Therapeutic based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.333
Price to Book Ratio (EOD)Between0-11.416
Net Profit Margin (MRQ)Greater than0-4.424
Operating Margin (MRQ)Greater than0-4.805
Quick Ratio (MRQ)Greater than116.337
Current Ratio (MRQ)Greater than19.130
Debt to Asset Ratio (MRQ)Less than10.127
Debt to Equity Ratio (MRQ)Less than10.146
Return on Equity (MRQ)Greater than0.15-0.152
Return on Assets (MRQ)Greater than0.05-0.132
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Sage Therapeutic based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.463
Ma 20Greater thanMa 508.931
Ma 50Greater thanMa 1007.641
Ma 100Greater thanMa 2007.599
OpenGreater thanClose9.190
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Sage Therapeutic

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-12 12:34:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Sage Therapeutic earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • A Net Profit Margin of -442.4%ย means thatย $-4.42 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sage Therapeutic:

  • The MRQ is -442.4%. The company is making a huge loss. -2
  • The TTM is -791.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-442.4%TTM-791.6%+349.2%
TTM-791.6%YOY-3,829.7%+3,038.2%
TTM-791.6%5Y-4,927.3%+4,135.8%
5Y-4,927.3%10Y-5,758.0%+830.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-442.4%-91.7%-350.7%
TTM-791.6%-140.3%-651.3%
YOY-3,829.7%-196.4%-3,633.3%
3Y-3,573.5%-247.9%-3,325.6%
5Y-4,927.3%-343.3%-4,584.0%
10Y-5,758.0%-488.1%-5,269.9%
4.3.1.2. Return on Assets

Shows howย efficientย Sage Therapeutic is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • -13.2% Return on Assets means thatย Sage Therapeutic generatedย $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sage Therapeutic:

  • The MRQ is -13.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.2%TTM-15.1%+1.9%
TTM-15.1%YOY-13.5%-1.7%
TTM-15.1%5Y-8.4%-6.7%
5Y-8.4%10Y-11.0%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-11.5%-1.7%
TTM-15.1%-11.5%-3.6%
YOY-13.5%-11.4%-2.1%
3Y-12.7%-11.7%-1.0%
5Y-8.4%-11.9%+3.5%
10Y-11.0%-13.7%+2.7%
4.3.1.3. Return on Equity

Shows how efficient Sage Therapeutic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • -15.2% Return on Equity means Sage Therapeutic generated $-0.15ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sage Therapeutic:

  • The MRQ is -15.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-17.3%+2.1%
TTM-17.3%YOY-15.1%-2.2%
TTM-17.3%5Y-9.5%-7.8%
5Y-9.5%10Y-12.2%+2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-13.6%-1.6%
TTM-17.3%-14.8%-2.5%
YOY-15.1%-14.4%-0.7%
3Y-14.2%-16.8%+2.6%
5Y-9.5%-17.5%+8.0%
10Y-12.2%-19.5%+7.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Sage Therapeutic.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Sage Therapeutic is operatingย .

  • Measures how much profit Sage Therapeutic makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • An Operating Margin of -480.5%ย means the company generated $-4.80 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sage Therapeutic:

  • The MRQ is -480.5%. The company is operating very inefficient. -2
  • The TTM is -812.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-480.5%TTM-812.0%+331.6%
TTM-812.0%YOY-3,749.1%+2,937.1%
TTM-812.0%5Y-4,942.7%+4,130.7%
5Y-4,942.7%10Y-5,895.7%+953.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-480.5%-221.8%-258.7%
TTM-812.0%-250.7%-561.3%
YOY-3,749.1%-208.5%-3,540.6%
3Y-3,752.2%-220.2%-3,532.0%
5Y-4,942.7%-342.4%-4,600.3%
10Y-5,895.7%-462.5%-5,433.2%
4.3.2.2. Operating Ratio

Measures how efficient Sage Therapeutic is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Biotechnology industry mean).
  • An Operation Ratio of 5.80 means that the operating costs are $5.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sage Therapeutic:

  • The MRQ is 5.797. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.539. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.797TTM9.539-3.743
TTM9.539YOY38.472-28.933
TTM9.5395Y50.506-40.967
5Y50.50610Y72.489-21.983
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7972.097+3.700
TTM9.5392.684+6.855
YOY38.4723.076+35.396
3Y38.6553.524+35.131
5Y50.5064.724+45.782
10Y72.4896.445+66.044
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Sage Therapeutic.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Sage Therapeutic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Biotechnology industry mean).
  • A Current Ratio of 9.13ย means the company has $9.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sage Therapeutic:

  • The MRQ is 9.130. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.128. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.130TTM9.128+0.002
TTM9.128YOY10.026-0.898
TTM9.1285Y15.958-6.830
5Y15.95810Y15.634+0.325
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.1303.638+5.492
TTM9.1283.846+5.282
YOY10.0264.140+5.886
3Y11.3364.688+6.648
5Y15.9585.722+10.236
10Y15.6346.144+9.490
4.4.3.2. Quick Ratio

Measures if Sage Therapeutic is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • A Quick Ratio of 16.34ย means the company can pay off $16.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sage Therapeutic:

  • The MRQ is 16.337. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.092. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ16.337TTM16.092+0.245
TTM16.092YOY17.713-1.620
TTM16.0925Y26.737-10.645
5Y26.73710Y24.432+2.305
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.3372.826+13.511
TTM16.0923.116+12.976
YOY17.7133.786+13.927
3Y20.1494.311+15.838
5Y26.7375.702+21.035
10Y24.4326.335+18.097
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Sage Therapeutic.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Sage Therapeuticย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Sage Therapeutic to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13ย means that Sage Therapeutic assets areย financed with 12.7% credit (debt) and the remaining percentage (100% - 12.7%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Sage Therapeutic:

  • The MRQ is 0.127. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.122+0.005
TTM0.122YOY0.101+0.021
TTM0.1225Y0.083+0.039
5Y0.08310Y0.0830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1270.327-0.200
TTM0.1220.349-0.227
YOY0.1010.332-0.231
3Y0.0980.340-0.242
5Y0.0830.346-0.263
10Y0.0830.378-0.295
4.5.4.2. Debt to Equity Ratio

Measures ifย Sage Therapeutic is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • A Debt to Equity ratio of 14.6% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sage Therapeutic:

  • The MRQ is 0.146. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.140. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.140+0.006
TTM0.140YOY0.113+0.027
TTM0.1405Y0.092+0.048
5Y0.09210Y0.093-0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.383-0.237
TTM0.1400.438-0.298
YOY0.1130.414-0.301
3Y0.1100.450-0.340
5Y0.0920.457-0.365
10Y0.0930.512-0.419
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings Sage Therapeutic generates.

  • Above 15 is considered overpriced butย always compareย Sage Therapeutic to theย Biotechnology industry mean.
  • A PE ratio of -2.00 means the investor is paying $-2.00ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sage Therapeutic:

  • The EOD is -2.333. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.001. Based on the earnings, the company is expensive. -2
  • The TTM is -1.437. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.333MRQ-2.001-0.332
MRQ-2.001TTM-1.437-0.563
TTM-1.437YOY-4.817+3.379
TTM-1.4375Y-4.495+3.057
5Y-4.49510Y-15.163+10.668
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.333-2.399+0.066
MRQ-2.001-2.092+0.091
TTM-1.437-2.625+1.188
YOY-4.817-3.784-1.033
3Y-3.501-3.762+0.261
5Y-4.495-6.363+1.868
10Y-15.163-7.055-8.108
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sage Therapeutic:

  • The EOD is -1.776. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.523. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.572. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.776MRQ-1.523-0.253
MRQ-1.523TTM-1.572+0.049
TTM-1.572YOY-4.639+3.067
TTM-1.5725Y-4.971+3.399
5Y-4.97110Y-128.433+123.462
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.776-3.299+1.523
MRQ-1.523-2.742+1.219
TTM-1.572-3.801+2.229
YOY-4.639-4.402-0.237
3Y-3.641-5.140+1.499
5Y-4.971-8.483+3.512
10Y-128.433-9.296-119.137
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Sage Therapeutic is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Biotechnology industry mean).
  • A PB ratio of 1.21 means the investor is paying $1.21ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sage Therapeutic:

  • The EOD is 1.416. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.215. Based on the equity, the company is underpriced. +1
  • The TTM is 0.962. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.416MRQ1.215+0.202
MRQ1.215TTM0.962+0.253
TTM0.962YOY1.982-1.020
TTM0.9625Y1.980-1.018
5Y1.98010Y6.648-4.669
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4162.113-0.697
MRQ1.2151.856-0.641
TTM0.9622.125-1.163
YOY1.9822.454-0.472
3Y1.5942.492-0.898
5Y1.9803.668-1.688
10Y6.6484.364+2.284
4.6.2. Total Gains per Share

2.4. Latest News of Sage Therapeutic

Does Sage Therapeutic still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Sage Therapeutic to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-05
15:51
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of ShareholdersRead
2025-07-01
21:22
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)Read
2025-06-25
20:45
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of ShareholdersRead
2025-06-16
15:14
Beleaguered Sage Snapped Up In Deal Worth Up To $561 MillionRead
2025-06-16
14:37
Sage Therapeutics shares soar after supernus acquisition dealRead
2025-06-16
14:29
Stocks making the biggest moves premarket: U.S. Steel, Roku, Celsius, Sarepta Therapeutics and moreRead
2025-06-16
13:27
Supernus to acquire depression drugmaker SageRead
2025-06-16
13:00
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sage Therapeutic.

4.8.1. Institutions holding Sage Therapeutic

Institutions are holding 83.648% of the shares of Sage Therapeutic.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc8.27510.000750772882391194.9423
2025-03-31BlackRock Inc7.59670.00084661072-189645-3.9096
2025-03-31Madison Avenue Partners, LP7.2983.0223447779844777980
2025-03-31Caligan Partners LP4.97515.0639305253800
2025-03-31Test Hedge Fund Mgmt4.45311.3586273227127322710
2025-03-31D. E. Shaw & Co LP3.40220.014820874431367338189.8804
2025-03-31Deep Track Capital, LP3.3230.5249203884520388450
2025-03-31Marshall Wace Asset Management Ltd2.87120.0178176167217616720
2025-03-31Morgan Stanley - Brokerage Accounts2.28010.00081398982-3195373-69.55
2025-03-31BOOTHBAY FUND MANAGEMENT, LLC2.25640.291384465-4038-0.2908
2025-03-31Geode Capital Management, LLC2.12430.00081303377464743.6975
2025-03-31Federated Hermes Inc1.94360.02051192489867107.8415
2025-03-31State Street Corp1.93720.00041188574-84076-6.6064
2025-03-31AQR Capital Management LLC1.86840.00941146379585950104.5538
2025-03-31Citadel Advisors Llc1.71070.001610496229652661144.2766
2025-03-31683 Capital Management LLC1.62980.5484100000037000058.7302
2025-03-31Renaissance Technologies Corp1.25450.009376970031890570.7428
2025-03-31ADAR1 Capital Management LLC1.21011.09587424957232953767.1615
2025-03-31Harvest Management LLC1.18362.54957262007262000
2025-03-31Jacobs Levy Equity Management, Inc.1.15130.0223706390-416918-37.1152
Total 62.744414.552638497600+12549793+32.6%

4.9.2. Funds holding Sage Therapeutic

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31BB Biotech AG Ord7.27020.9528446069300
2025-05-31Vanguard Total Stock Mkt Idx Inv2.96790.0006182097900
2025-05-31iShares Russell 2000 ETF2.23580.0144137180900
2025-03-31Vanguard Strategic Equity Inv1.7470.0997107187141284762.6452
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.4360.005288107873490.8411
2025-03-31Federated Hermes MDT Small Cap Core IS1.33920.5132821658522146.7859
2025-03-31Federated Hermes MDT SCC Institutional1.33920.5129821658522146.7859
2025-03-31Fidelity Small Cap Index0.88780.0179544744-2883-0.5265
2025-05-31iShares Russell 2000 Value ETF0.80930.029949652900
2025-03-31Vanguard Explorer Inv0.70520.017343267500
2025-04-30Nuveen Quant Small Cap Equity R60.70390.1023431860-10740-2.4266
2025-03-31Vanguard Strategic Small-Cap Equity Inv0.53950.1617330987-125723-27.528
2025-05-31iShares Biotechnology ETF0.52560.041732246900
2025-05-31State St Russell Sm/Mid Cpยฎ Indx SL Cl I0.51430.00531553600
2025-04-30Fidelity Extended Market Index0.48320.006296446-2833-0.9466
2025-05-31Vanguard Russell 2000 ETF0.450.014127612924380.8908
2025-05-31Schwab US Small-Cap ETFโ„ข0.42020.0101257803-666-0.2577
2025-03-31Federated Hermes MDT Small Cap Growth IS0.41060.448225193900
2025-03-31Federated Hermes MDT SCG Institutional0.41060.448625193900
2025-05-31Selectra J. Lamarck Biotech A0.39882.43852447009040058.5872
Total 25.59435.840115703502+474617+3.0%

5.3. Insider Transactions

Insiders are holding 10.407% of the shares of Sage Therapeutic.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-09Elizabeth BarrettBUY200018.64
2023-05-09Elizabeth BarrettBUY100050.5
2023-02-10Jeffrey M JonasSELL1164344.61
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets469,669
Total Liabilities59,821
Total Stockholder Equity409,848
 As reported
Total Liabilities 59,821
Total Stockholder Equity+ 409,848
Total Assets = 469,669

Assets

Total Assets469,669
Total Current Assets454,476
Long-term Assets15,193
Total Current Assets
Cash And Cash Equivalents 45,224
Short-term Investments 378,630
Net Receivables 10,729
Other Current Assets 19,893
Total Current Assets  (as reported)454,476
Total Current Assets  (calculated)454,476
+/-0
Long-term Assets
Property Plant Equipment 11,135
Long-term Assets Other 4,058
Long-term Assets  (as reported)15,193
Long-term Assets  (calculated)15,193
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities49,778
Long-term Liabilities10,043
Total Stockholder Equity409,848
Total Current Liabilities
Short-term Debt 1,812
Accounts payable 5,435
Other Current Liabilities 42,531
Total Current Liabilities  (as reported)49,778
Total Current Liabilities  (calculated)49,778
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt10,043
Long-term Liabilities  (as reported)10,043
Long-term Liabilities  (calculated)10,043
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -3,032,539
Accumulated Other Comprehensive Income 142
Other Stockholders Equity 3,442,239
Total Stockholder Equity (as reported)409,848
Total Stockholder Equity (calculated)409,848
+/-0
Other
Capital Stock6
Cash and Short Term Investments 423,854
Common Stock Shares Outstanding 61,858
Liabilities and Stockholders Equity 469,669
Net Debt -33,369
Net Invested Capital 409,848
Net Working Capital 404,698
Property Plant and Equipment Gross 11,135
Short Long Term Debt Total 11,855



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
2,995
0
0
0
8,532
56,777
51,651
137,963
129,665
115,478
228,473
208,410
189,016
303,510
275,630
436,301
404,531
351,168
293,412
251,085
529,937
1,100,652
1,129,483
1,046,999
952,705
1,422,914
1,315,547
1,203,727
1,084,150
944,973
827,242
738,628
2,159,246
2,080,698
2,015,475
1,927,180
1,825,288
1,705,703
1,601,377
1,486,073
1,356,449
1,220,686
1,082,288
949,663
882,277
767,600
697,105
622,432
547,222
469,669
469,669547,222622,432697,105767,600882,277949,6631,082,2881,220,6861,356,4491,486,0731,601,3771,705,7031,825,2881,927,1802,015,4752,080,6982,159,246738,628827,242944,9731,084,1501,203,7271,315,5471,422,914952,7051,046,9991,129,4831,100,652529,937251,085293,412351,168404,531436,301275,630303,510189,016208,410228,473115,478129,665137,96351,65156,7778,5320002,995
   > Total Current Assets 
0
2,802
0
0
8,407
56,660
51,543
137,790
128,822
114,529
227,508
207,481
188,491
302,606
274,107
434,688
402,579
349,044
291,120
248,343
525,075
1,095,088
1,123,769
1,039,912
944,695
1,371,532
1,263,570
1,152,663
1,035,093
898,236
785,384
698,884
2,122,370
2,051,866
1,988,599
1,901,697
1,800,643
1,682,244
1,578,884
1,465,104
1,272,494
1,203,437
1,002,616
933,270
869,350
755,442
686,811
604,987
531,301
454,476
454,476531,301604,987686,811755,442869,350933,2701,002,6161,203,4371,272,4941,465,1041,578,8841,682,2441,800,6431,901,6971,988,5992,051,8662,122,370698,884785,384898,2361,035,0931,152,6631,263,5701,371,532944,6951,039,9121,123,7691,095,088525,075248,343291,120349,044402,579434,688274,107302,606188,491207,481227,508114,529128,822137,79051,54356,6608,407002,8020
       Cash And Cash Equivalents 
2,802
-2,802
0
0
8,066
55,425
49,127
136,727
127,766
113,162
224,234
204,877
186,753
299,680
189,003
320,078
168,517
145,460
133,450
134,916
306,235
557,555
325,830
253,123
190,943
342,295
166,185
259,181
126,705
199,444
258,228
184,270
1,661,082
899,250
514,158
422,165
294,233
178,674
206,510
199,826
162,700
206,557
121,416
148,712
70,992
173,985
101,233
99,627
81,021
45,224
45,22481,02199,627101,233173,98570,992148,712121,416206,557162,700199,826206,510178,674294,233422,165514,158899,2501,661,082184,270258,228199,444126,705259,181166,185342,295190,943253,123325,830557,555306,235134,916133,450145,460168,517320,078189,003299,680186,753204,877224,234113,162127,766136,72749,12755,4258,06600-2,8022,802
       Short-term Investments 
0
5,604
0
0
0
0
0
0
0
0
0
0
0
0
83,292
111,192
228,962
197,104
152,478
108,535
212,613
525,958
766,603
768,278
731,833
1,008,956
1,070,364
863,069
881,688
673,313
498,294
484,267
438,467
1,104,767
1,397,157
1,421,004
1,448,063
1,446,567
1,307,197
1,193,813
1,109,794
923,028
881,200
727,340
682,192
544,360
546,892
469,527
423,397
378,630
378,630423,397469,527546,892544,360682,192727,340881,200923,0281,109,7941,193,8131,307,1971,446,5671,448,0631,421,0041,397,1571,104,767438,467484,267498,294673,313881,688863,0691,070,3641,008,956731,833768,278766,603525,958212,613108,535152,478197,104228,962111,19283,2920000000000005,6040
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,378
0
0
0
0
0
0
0
0
0
0
24,766
48,438
24,185
18,506
19,797
23,722
18,448
13,660
15,002
15,090
22,513
83,009
14,109
13,743
14,871
9,134
10,729
10,7299,13414,87113,74314,10983,00922,51315,09015,00213,66018,44823,72219,79718,50624,18548,43824,766000000000018,3780000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,400
0
0
0
-64,486
-15,002
-61,411
0
1,332
0
0
-18,071
0
0
00-18,071001,3320-61,411-15,002-64,4860001,400000000000000000000000000000000000000
   > Long-term Assets 
0
-2,802
0
0
125
117
108
173
843
949
965
929
525
904
1,523
1,613
1,952
2,124
2,292
2,742
4,862
5,564
5,714
7,087
8,010
51,382
51,977
51,064
49,057
46,737
41,858
39,744
36,876
28,832
26,876
25,483
24,645
23,459
22,493
20,969
83,955
17,249
79,672
16,393
12,927
12,158
10,294
17,445
15,921
15,193
15,19315,92117,44510,29412,15812,92716,39379,67217,24983,95520,96922,49323,45924,64525,48326,87628,83236,87639,74441,85846,73749,05751,06451,97751,3828,0107,0875,7145,5644,8622,7422,2922,1241,9521,6131,52390452592996594984317310811712500-2,8020
       Property Plant Equipment 
130
0
0
0
86
78
69
134
163
269
285
249
286
865
959
1,049
1,952
1,560
1,443
2,742
4,862
4,295
4,445
5,168
8,010
44,637
45,587
44,879
42,897
40,676
36,076
33,950
31,819
24,171
22,008
20,339
19,125
17,599
16,317
14,791
13,430
11,725
10,040
8,468
6,379
4,442
2,494
12,270
11,643
11,135
11,13511,64312,2702,4944,4426,3798,46810,04011,72513,43014,79116,31717,59919,12520,33922,00824,17131,81933,95036,07640,67642,89744,87945,58744,6378,0105,1684,4454,2954,8622,7421,4431,5601,9521,049959865286249285269163134697886000130
       Long-term Assets Other 
0
-2,802
0
0
39
39
39
39
39
39
39
39
239
39
564
564
564
564
849
849
849
1,269
1,269
1,919
2,367
6,745
6,390
6,185
6,160
6,061
5,782
5,794
5,057
3,392
3,599
3,875
4,251
4,591
4,907
4,909
69,256
4,255
68,300
6,593
6,548
6,216
7,800
5,175
4,278
4,058
4,0584,2785,1757,8006,2166,5486,59368,3004,25569,2564,9094,9074,5914,2513,8753,5993,3925,0575,7945,7826,0616,1606,1856,3906,7452,3671,9191,2691,26984984984956456456456439239393939393939393900-2,8020
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
641
641
641
641
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000064164164164100000000
> Total Liabilities 
1,419
0
0
0
40,068
3,124
96,443
5,044
7,780
8,968
11,022
10,306
15,321
16,010
18,421
22,564
36,014
32,722
33,108
51,033
54,462
41,376
51,720
58,494
89,734
103,380
112,672
122,656
139,495
95,767
87,327
81,047
86,912
77,422
85,963
91,526
96,257
87,201
97,141
105,951
103,850
87,557
97,912
133,004
82,747
61,799
69,043
70,597
82,133
59,821
59,82182,13370,59769,04361,79982,747133,00497,91287,557103,850105,95197,14187,20196,25791,52685,96377,42286,91281,04787,32795,767139,495122,656112,672103,38089,73458,49451,72041,37654,46251,03333,10832,72236,01422,56418,42116,01015,32110,30611,0228,9687,7805,04496,4433,12440,0680001,419
   > Total Current Liabilities 
1,419
0
0
0
2,315
3,088
3,931
5,010
7,757
8,945
11,000
10,291
15,307
15,970
18,339
22,330
35,169
31,882
32,281
49,837
51,951
37,872
47,919
54,526
86,030
68,376
78,953
90,956
112,128
70,360
64,292
59,665
67,204
62,011
71,898
78,942
85,193
77,703
89,241
99,687
99,259
84,692
96,807
133,004
82,747
61,799
69,043
60,406
71,615
49,778
49,77871,61560,40669,04361,79982,747133,00496,80784,69299,25999,68789,24177,70385,19378,94271,89862,01167,20459,66564,29270,360112,12890,95678,95368,37686,03054,52647,91937,87251,95149,83732,28131,88235,16922,33018,33915,97015,30710,29111,0008,9457,7575,0103,9313,0882,3150001,419
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,149
0
0
20,488
20,540
17,154
17,240
17,324
14,612
14,716
14,828
14,936
15,046
15,126
15,206
15,286
15,368
15,450
13,934
5,165
3,306
2,822
166
1,318
1,812
1,8121,3181662,8223,3065,16513,93415,45015,36815,28615,20615,12615,04614,93614,82814,71614,61217,32417,24017,15420,54020,488007,1490000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,149
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000007,1490000000000000000000000000
       Accounts payable 
1,314
0
0
0
1,988
1,626
1,862
2,157
2,429
2,782
5,195
3,246
5,159
4,540
5,957
5,237
12,817
8,230
6,042
13,030
9,350
8,350
8,338
5,879
34,036
13,556
12,431
5,041
15,266
7,910
2,387
4,289
3,691
3,285
2,917
4,733
10,450
7,129
5,410
7,077
18,950
12,263
9,283
11,136
10,318
6,479
8,650
7,126
12,699
5,435
5,43512,6997,1268,6506,47910,31811,1369,28312,26318,9507,0775,4107,12910,4504,7332,9173,2853,6914,2892,3877,91015,2665,04112,43113,55634,0365,8798,3388,3509,35013,0306,0428,23012,8175,2375,9574,5405,1593,2465,1952,7822,4292,1571,8621,6261,9880001,314
       Other Current Liabilities 
105
0
0
0
327
1,462
2,069
2,853
5,328
6,163
5,805
7,045
10,148
11,430
12,382
17,093
22,352
23,652
26,239
36,807
42,601
29,522
39,581
48,647
51,994
54,820
66,522
85,915
76,374
41,910
44,751
38,136
46,189
44,114
54,265
59,381
59,807
55,528
68,705
77,404
65,023
57,061
72,074
107,934
67,264
52,014
57,571
53,114
57,598
42,531
42,53157,59853,11457,57152,01467,264107,93472,07457,06165,02377,40468,70555,52859,80759,38154,26544,11446,18938,13644,75141,91076,37485,91566,52254,82051,99448,64739,58129,52242,60136,80726,23923,65222,35217,09312,38211,43010,1487,0455,8056,1635,3282,8532,0691,462327000105
   > Long-term Liabilities 
0
0
0
0
37,753
36
92,512
34
23
23
22
15
14
40
82
234
845
840
827
1,196
2,511
3,504
3,801
3,968
3,704
35,004
33,719
31,700
27,367
25,407
23,035
21,382
19,708
15,411
14,065
12,584
11,064
9,498
7,900
6,264
4,591
2,865
1,105
0
0
0
0
10,191
10,518
10,043
10,04310,51810,19100001,1052,8654,5916,2647,9009,49811,06412,58414,06515,41119,70821,38223,03525,40727,36731,70033,71935,0043,7043,9683,8013,5042,5111,196827840845234824014152223233492,5123637,7530000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
641
641
641
641
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000064164164164100000000
       Warrants
0
0
0
0
0
0
92,472
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000092,472000000
       Other Liabilities 
0
0
0
0
44
36
40
34
23
23
22
15
14
40
82
234
845
840
827
1,196
2,511
3,504
3,801
3,968
3,704
476
410
340
519
456
374
313
270
0
101
103
100
0
100
100
100
0
102
0
0
0
0
0
0
0
00000001020100100100010010310102703133744565193404104763,7043,9683,8013,5042,5111,19682784084523482401415222323344036440000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000200000000000000
> Total Stockholder Equity
1,576
1,576
0
0
-31,536
53,653
-44,792
132,919
121,885
106,510
217,451
198,104
173,695
287,500
257,209
413,737
368,517
318,446
260,304
200,052
475,475
1,059,276
1,077,763
988,505
862,971
1,319,534
1,202,875
1,081,071
944,655
849,206
739,915
657,581
2,072,334
2,003,276
1,929,512
1,835,654
1,729,031
1,618,502
1,504,236
1,380,122
1,252,599
1,133,129
984,376
816,659
799,530
705,801
628,062
551,835
465,089
409,848
409,848465,089551,835628,062705,801799,530816,659984,3761,133,1291,252,5991,380,1221,504,2361,618,5021,729,0311,835,6541,929,5122,003,2762,072,334657,581739,915849,206944,6551,081,0711,202,8751,319,534862,971988,5051,077,7631,059,276475,475200,052260,304318,446368,517413,737257,209287,500173,695198,104217,451106,510121,885132,919-44,79253,653-31,536001,5761,576
   Common Stock
0
0
0
0
0
2
0
3
3
3
3
3
3
3
3
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
66666666666666666655555555555544444333333330200000
   Retained Earnings Total Equity00000000-2,174,998-2,028,170-1,881,024-1,743,701-1,617,441-1,495,386-1,370,674-1,240,503-1,133,258-1,037,494-2,012,389-1,906,654-1,770,307-1,643,567-1,474,914-1,294,956-1,126,735-963,329-804,941-682,023-665,045-590,447-521,025-447,306-377,105-320,327-264,426-226,630-191,883-161,340-132,778-108,743-83,716-66,845-54,484-44,792000000
   Accumulated Other Comprehensive Income 
0
-13,394
0
0
-95
0
0
-137,963
-146
0
0
0
-261
0
39
-35
-102
-81
-67
-15
-29
-185
-145
-257
-515
-106
1,575
1,777
1,295
-792
1,709
946
415
-236
-285
-306
-2,660
-11,201
-13,872
-14,883
-10,206
-5,088
-5,644
-3,735
-814
-787
-691
901
244
142
142244901-691-787-814-3,735-5,644-5,088-10,206-14,883-13,872-11,201-2,660-306-285-2364159461,709-7921,2951,7771,575-106-515-257-145-185-29-15-67-81-102-35390-261000-146-137,96300-9500-13,3940
   Capital Surplus 
0
0
0
0
0
0
0
187,400
188,727
190,223
326,191
330,879
335,032
479,380
483,797
678,194
688,959
695,645
707,690
721,105
1,066,059
1,724,712
1,760,137
1,793,909
1,827,021
2,446,770
2,496,651
2,554,603
2,587,322
2,620,700
2,645,255
2,669,419
3,109,807
3,137,164
3,170,694
3,207,028
3,227,471
3,247,538
3,262,203
3,276,423
3,291,369
3,313,609
0
0
0
0
0
0
0
0
000000003,313,6093,291,3693,276,4233,262,2033,247,5383,227,4713,207,0283,170,6943,137,1643,109,8072,669,4192,645,2552,620,7002,587,3222,554,6032,496,6512,446,7701,827,0211,793,9091,760,1371,724,7121,066,059721,105707,690695,645688,959678,194483,797479,380335,032330,879326,191190,223188,727187,4000000000
   Treasury Stock00000000000000000000-400-400-400-400-400-211-211-211-211-113-17-17-17-170000000000000000
   Other Stockholders Equity 
0
0
0
0
-37,475
91,116
-92,472
325,363
188,727
190,223
326,191
330,879
335,032
479,380
483,797
678,194
688,942
695,628
707,673
721,088
1,065,946
1,724,501
1,759,926
1,793,698
1,826,810
2,446,370
2,496,251
2,554,203
2,586,922
2,620,300
2,644,855
2,669,019
3,109,407
3,136,764
3,170,294
3,206,628
3,227,071
3,247,138
3,261,803
3,276,023
3,290,969
3,313,209
3,325,337
3,357,341
3,369,997
3,384,724
3,409,743
3,425,475
3,435,164
3,442,239
3,442,2393,435,1643,425,4753,409,7433,384,7243,369,9973,357,3413,325,3373,313,2093,290,9693,276,0233,261,8033,247,1383,227,0713,206,6283,170,2943,136,7643,109,4072,669,0192,644,8552,620,3002,586,9222,554,2032,496,2512,446,3701,826,8101,793,6981,759,9261,724,5011,065,946721,088707,673695,628688,942678,194483,797479,380335,032330,879326,191190,223188,727325,363-92,47291,116-37,4750000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue41,243
Cost of Revenue-9,444
Gross Profit31,79931,799
 
Operating Income (+$)
Gross Profit31,799
Operating Expense-464,169
Operating Income-432,370-432,370
 
Operating Expense (+$)
Research Development225,895
Selling General Administrative216,420
Selling And Marketing Expenses0
Operating Expense464,169442,315
 
Net Interest Income (+$)
Interest Income31,675
Interest Expense-0
Other Finance Cost-0
Net Interest Income31,675
 
Pretax Income (+$)
Operating Income-432,370
Net Interest Income31,675
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-400,666-464,074
EBIT - interestExpense = -410,516
-801,332
-400,666
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-410,516-400,666
Earnings Before Interest and Taxes (EBITDA)-409,485
 
After tax Income (+$)
Income Before Tax-400,666
Tax Provision-0
Net Income From Continuing Ops-400,666-400,666
Net Income-400,666
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses473,613
Total Other Income/Expenses Net31,704-31,675
 

Technical Analysis of Sage Therapeutic
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sage Therapeutic. The general trend of Sage Therapeutic is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sage Therapeutic's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Sage Therapeutic Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sage Therapeutic.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 9.33 < 9.76 < 11.44.

The bearish price targets are: 9.04 > 8.81 > 8.76.

Know someone who trades $SAGE? Share this with them.๐Ÿ‘‡

Sage Therapeutic Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sage Therapeutic. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sage Therapeutic Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sage Therapeutic. The current macd is 0.48319542.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sage Therapeutic price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sage Therapeutic. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sage Therapeutic price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sage Therapeutic Daily Moving Average Convergence/Divergence (MACD) ChartSage Therapeutic Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sage Therapeutic. The current adx is 48.83.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sage Therapeutic shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Sage Therapeutic Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sage Therapeutic. The current sar is 8.54915246.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sage Therapeutic Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sage Therapeutic. The current rsi is 73.46. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Sage Therapeutic Daily Relative Strength Index (RSI) ChartSage Therapeutic Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sage Therapeutic. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sage Therapeutic price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sage Therapeutic Daily Stochastic Oscillator ChartSage Therapeutic Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sage Therapeutic. The current cci is 48.23.

Sage Therapeutic Daily Commodity Channel Index (CCI) ChartSage Therapeutic Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sage Therapeutic. The current cmo is 52.38.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sage Therapeutic Daily Chande Momentum Oscillator (CMO) ChartSage Therapeutic Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sage Therapeutic. The current willr is -28.125.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sage Therapeutic is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sage Therapeutic Daily Williams %R ChartSage Therapeutic Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Sage Therapeutic.

Sage Therapeutic Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sage Therapeutic. The current atr is 0.21679753.

Sage Therapeutic Daily Average True Range (ATR) ChartSage Therapeutic Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sage Therapeutic. The current obv is -4,829,067.

Sage Therapeutic Daily On-Balance Volume (OBV) ChartSage Therapeutic Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sage Therapeutic. The current mfi is 48.78.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sage Therapeutic Daily Money Flow Index (MFI) ChartSage Therapeutic Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sage Therapeutic.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Sage Therapeutic Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sage Therapeutic based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.463
Ma 20Greater thanMa 508.931
Ma 50Greater thanMa 1007.641
Ma 100Greater thanMa 2007.599
OpenGreater thanClose9.190
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Sage Therapeutic with someone you think should read this too:
  • Are you bullish or bearish on Sage Therapeutic? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sage Therapeutic? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sage Therapeutic

I send you an email if I find something interesting about Sage Therapeutic.


Comments

How you think about this?

Leave a comment

Stay informed about Sage Therapeutic.

Receive notifications about Sage Therapeutic in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.